Free tool
FAERS Monitor: Veopoz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761339 or its brand name (Veopoz, Pozelimab-Bbfg). Reports on generic versions are filed under their own applications.
Reports
4
Serious
4
100% of reports
Hospitalization
1
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug effect less than expected1
- hepatitis1
- injection site reaction1
- meningococcal infection1
- seizure1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| meningococcal infection | 1 | 16709.6 | 3049.5 | 4,163 |
| drug effect less than expected | 1 | 354.9 | 65.0 | 88 |
| hepatitis | 1 | 205.5 | 37.6 | 50 |
| injection site reaction | 1 | 76.4 | 14.0 | 18 |
| seizure | 1 | 45.5 | 8.3 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.